Abstract
Controversies exist about the definition and epidemiology of breakthrough cancer pain (BTcP), the pharmacological treatment options, drug dosing, and how to select the medications for BTcP among the new fentanyl products. Existing data were critically evaluated to provide recommendations by an expert group. An algorithm to diagnose BTcP should be used followed by a careful assessment. Fentanyl products provide efficacy and rapidity of action to counteract the temporal pattern of BTcP. The doses of opioids used for background pain should guide the choice of the doses of fentanyl products. The choice of fentanyl products should be based on individual clinical conditions.
Similar content being viewed by others
References
Portenoy RK, Hagen NA (1990) Breakthrough pain: definition, prevalence and characteristics. Pain 41:273–281
Portenoy RK et al (1999) Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 81:129–134
Mercadante S et al (2015) Italian Oncologic Pain Survey (IOPS): a multi-centre Italian study of breakthrough pain performed in different settings. Clin J Pain 31:214–221
Caraceni A et al (2004) Working Group of an IASP Task Force on Cancer Pain. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med 18:177–183
Mercadante S et al (2009) Breakthrough pain advanced cancer patients : a longitudinal study. Support Care Cancer 38:554–560
Mercadante S et al (2010) Breakthrough pain in oncology : a longitudinal study. J Pain Symptom Manag 40:183–190
Mercadante S et al (2013) Meaningful cut-off pain intensity for breakthrough pain changes in advanced cancer patients. Curr Med Res Opin 29:93–97
Mercadante S et al (2013) Relationship between background cancer pain, breakthrough pain, and analgesic treatment: a preliminary study for a better interpretation of epidemiological and clinical studies. Curr Med Res Opin 29:667–671
Caraceni A et al (2012) Episodic (breakthrough) pain prevalence in a population of cancer pain patients. Comparison of clinical diagnoses with the QUDEI—Italian questionnaire for intense episodic pain. J Pain Symptom Manag 43:833–841
Greco MT et al (2011) Epidemiology and pattern of care of breakthrough cancer pain in a longitudinal sample of cancer patients. Results from the Cancer Pain Outcome Research Study Group. Clin J Pain 27:9–18
Gómez-Batiste X et al (2002) Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain. J Pain Symptom Manag 24:45–52
Zeppetella G et al (2000) Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manag 20:87–92
Svendsen KB et al (2005) Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain 9:195–206
Swanwick M (2001) The prevalence of episodic pain in cancer: a survey of hospice patients on admission. Palliat Med 15:9–18
Petzke F, Radbruch L, Zech D, Loick G, Grond S et al (1999) Temporal presentation of chronic cancer pain: transitory pains on admission to a multidisciplinary pain clinic. J Pain Symptom Manag 17:391–401
Davies A et al (2011) Multi-centre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies. Eur J Pain 15:756–763
Bennett D et al (2005) Consensus panel recommendations for the assessment and management of breakthrough pain. Part 2—management. Pharm Ther 30:354–361
Hagen NA et al (2008) The Alberta Breakthrough pain assessment tool for cancer patients. A validation study using a Delphi process and patient think-alounr interview. J Pain Symptom Manag 35:136–152
Davies A et al (2013) Breakthrough cancer pain: an observational study of 1000 European oncology patients. J Pain Symptom Manag 46:619–628
Mercadante S et al (2014) Breakthrough pain in patients with abdominal cancer pain. Clin J Pain 30:510–514
Haugen D et al (2010) Assessment and classification of cancer breakthrough pain: a systematic literature review. Pain 149:476–482
Hagen NA et al (2007) A titration strategy is needed to manage breakthrough cancer pain effectively: observations from data pooled from three clinical trials. J Palliat Med 10:47–55
Webber K et al (2014) Development and validation of the breakthrough pain assessment tool (BAT) in cancer patients. J Pain Symptom Manag 48:619
Mercadante S et al (2004) Optimization of opioid therapy for preventing incident pain associated with bone metastases. J Pain Symptom Manag 28:505–510
Hanks GW et al (2001) Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 84:587–593
Zeppetella G (2013) Evidence-based treatment of cancer-related breakthrough pain with opioids. J Natl Compr Cancer Netw 11:S37–S43
Mercadante S (2012) Pharmacotherapy for breakthrough cancer pain. Drugs 72:181–190
Jandhyala R et al (2013) Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials. J Pain Symptom Manag 46:573–580
Zeppetella G, Davies AN (2013) Opioids for the management of breakthrough pain in cancer patients. Cochrane Database Syst Rev 10:CD004311. doi:10.1002/14651858.CD004311.pub3
Bedard G et al (2013) A survey of Canadian cancer patients’ perspectives on the characteristics and treatment of breakthrough pain. Support Care Cancer 21:2557–2563
Davies AN et al (2009) The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 13:331–338
Mercadante S (2009) Breakthrough pain: on the road again. Eur J Pain 13:329–430
Mercadante S (2011) The use of rapid onset opioids for breakthrough cancer pain: the challenge of its dosing. Crit Rev Oncol Hematol 80:460–465
Mercadante S (2011) Rapid onset opioids for breakthrough pain: titrating or not titrating, this is the question. Eur J Pain (Suppl. 2): 443-448
Zeppetella GB (2008) Opioids for cancer breakthrough pain: a pilot study reporting patient assessment of time to meaningful pain relief. J Pain Symptom Manag 35:563–567
Webber K et al (2011) Breakthrough pain: a qualitative study involving patients with advanced cancer. Support Care Cancer 19:2041–2046
Mercadante S et al (2013) The use of sublingual fentanyl for breakthrough pain by using doses proportional to opioid basal regimen. Curr Med Res Opin 29:1527–1532
Mercadante S et al (2013) The use of fentanyl buccal tablets for breakthrough pain by using doses proportional to opioid basal regimen in a home care setting. Support Care Cancer 21:2335–2339
Mercadante S et al (2007) Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain. Br J Cancer 96:1828–1833
Mercadante S (2006) Fentanyl buccal tablet in breakthrough pain in opioid-tolerant patients with cancer. Drugs 66:2394–2395
Mercadante S et al (2012) Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses. Curr Med Res Opin 28:963–968
England R et al (2011) How practical are transmucosal fentanyl products for breakthrough cancer pain? A survey of user opinion. BMJ Support Palliat Care 1:349–351
Mercadante S et al (2014) Intranasal fentanyl versus fentanyl pectin nasal spray for the management of breakthrough cancer pain in doses proportional to basal opioid regimen. J Pain 15:602–607
Mercadante S et al (2014) Patients’ acceptability of different fentanyl products for breakthrough cancer pain. Clin Oncol 26:806
Conflict of interest
IOPS activity is sponsored by an unrestricted grant of Molteni Pharmaceutical, Italy.
The authors had full control of all primary data and agree to allow the journal to review their data if requested.
Author information
Authors and Affiliations
Consortia
Corresponding author
Additional information
An erratum to this article is available at http://dx.doi.org/10.1007/s00520-017-3739-z.
Appendix
Appendix
The IOPS MS Study Group
Mediati Rocco Domenico6, Caruselli Amanda1,Costanzi Andrea2, Russo Gennaro3, Bracchi Paola4, Dodaro Lucia5, Contu Viviana8, Fora Gianluca8, Veronese Barbara10, Alu Massimiliano11, Chiurazzi Bruno12, Sgarlata Massimiliano13, Kasa Alma14, Donelli Emanuela15, Silvestro Stefania15, Romano Carmela17, Ghidoni Silvia18, Palermo Loredana19, Pisanu Giovanni Maria 20, Imperatori Luca21, Diacciati Sara22, Samolsky Dekel Boaz23, Bruno Emanuela24, Saulle Serena25, Bonotto Marta26, De santis Stefano27, Tammaro Dario28, Ginocchi Laura29, Zampieri Mari31, Fioroni Iacopo32, Gallo Gloria33, Saber Benhaz33.
Dauri Mario7, Airoldi Mario8, Azzarello Giuseppe9, Bandera Mauro10, Blasi Livio11, Carteni Giacomo12, Costanzo Veruska13, Degiovanni Daniela14, Fusco Flavio15, Guardamagna Vittorio16, Iaffaioli Vincenzo17, Lazzari Marzia7, Liguori Simeone18, Lorusso Vito19, Mameli Sergio 20, Mattioli Rodolfo21, Mazzei Teresita22, Melotti Rita Maria23, Menardo Valentino24, Miotti Danilo25, Moroso Stefano26, Natoli Silvia7, Orsetti Remo27, Papa Alfonso28, Ricci Sergio29, Sabato Alessandro Fabrizio7, Scelzi Elvira30, Sofia Michele31, Tonini Giuseppe32, Valle Alessandro33
6 Pain Relief, Palliative Care, Oncology Department, Careggi Hospital, Florence Primary Care Unit, ASL RME, Rome,
7 Emergency care, Critical care Medicine, pain Medicine and Anesthesiologydepartement, Tor Vergata University of Rome
8 2nd Medical Oncology Division, Cittàdella Salute e dellaScienza Hospital of Turin, Turin
9 Dip SpecialitàMediche, UOCOncologiaedEmatologiaOncologica; ASL 13 Mirano, Venezia, Italia
10 Ospedaliera Papa Giovanni XXIII - Unit of Paliative Care and Pain Therapy, Bergamo, Italy
11 Medical Oncology Unit, ARNAS Civico, Palermo
12 Medical Oncology, A.O.R.N A. Cardarelli, Naples
13 Palliative Care Unit, SAMO ONLUS, Catania
14 Palliative Care Unit, Ospedale S. Spirito, CasaleMonferrato, Italy
15 SSD Cure Palliative Dipartimento Cure PrimarieedAttivitàDistrettuali ASL3 Genovese
16 UnitàOperativa di Cire Palliative e Terapia del dolore - IRCCS IstitutoEuropeo di Oncologia (IEO) - Milano, Italia
17 Abdominal Medical Oncology, National Cancer Institute, IRCCS Foundation Pascale, Naples
18 Ospedaliera Papa Giovanni XXIII - Unit of Palliative Care and Pain Therapy, Bergamo, Italy
19 Medical Oncology Unit, National Cancer Research Centre "Giovanni Paolo II", Bari
20 Pain Therapy Unit, “A. Businco” Hospital, ASL 8, Cagliari, Italy
21 S. Croce Hospital, Medical Oncology Unit, Fano - Pesaro, Italy
22 Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence
23 Department of Medicine and Surgery Sciences, University of Bologna, Bologna
24 StrutturaSempliceAlgologia, A.O. S. Croce e Carle, Cuneo, Italy
25 Salvatore Maugeri, Foundation IRCCS, Pavia, Italy
26 Medical Oncology, University Hospital S. Maria dellaMisericordia, Udine, Italy
27 Pain Medicine Unit, S. Camillo-Forlanini Hospital, Rome
28 Pain Relief, A.O. Dei Colli, Monaldi Hospital, Naples
29 Division of Medical Oncology, Department of Oncology, S. Chiara University Hospital, Pisa
30 U.O OncologiaMedica, P.O. Castelfranco Veneto- Treviso, Italy
31 U.O.C. Cure Palliative, Hospice e Medicina del Dolore. P.O di GarbagnateM.se, Milano
32 Department of Medical Oncology, Campus Bio-Medico University of Rome
33 Cure Palliative, Fondazione FARO, Torino
Rights and permissions
About this article
Cite this article
Mercadante, S., Marchetti, P., Cuomo, A. et al. Breakthrough pain and its treatment: critical review and recommendations of IOPS (Italian Oncologic Pain Survey) expert group. Support Care Cancer 24, 961–968 (2016). https://doi.org/10.1007/s00520-015-2951-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-015-2951-y